Ikuo Nakamura

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 488 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Effect of Interferon Therapy on Hepatocellular Carcinogenesis in Patients With Chronic Hepatitis Type C: A Long–Term Observation Study of 1,643 Patients Using Statistical Bias Correction With Proportional Hazard Analysis

Kenji Ikeda, Satoshi Saitoh, Yasuji Arase et al. · Hepatology · 1999 · 467 citations · Full text

Medicine, Oncology, Pathology +17

Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial

Kohei Nakachi, Masafumi Ikeda, Masaru Konishi et al. · The Lancet · 2023 · 232 citations

Medicine, Oncology, Surgery +11

HLA B44-restricted cytotoxic T lymphocytes recognizing an epitope on hepatitis C virus nucleocapsid protein

Hiroto Kita, Takashi Moriyama, Takashi Kaneko et al. · Hepatology · 1993 · 121 citations

Life Sciences, Immunology, Molecular Biology +14

Hepatitis B core antigen stimulates interleukin-10 secretion by both T cells and monocytes from peripheral blood of patients with chronic hepatitis B virus infection

N Hyodo, Ikuo Nakamura, Michio Imawari · Clinical & Experimental Immunology · 2004 · 74 citations · Full text

Life Sciences, Immunology, Infectious Diseases +13